Figure 2
Pharicin B accumulates RAR-α protein in the presence of ATRA in AML cell lines and some primary cells. Cells were treated with pharicin B (2μM) and/or ATRA (10−8M for NB4 and 10−7M for U937 and THP-1) for 24 and 48 hours (A), and primary AML cells isolated from newly diagnosed patients (number represents patient numbers listed in Table 1) were treated with 2μM pharicin B and/or 10−7M ATRA for 48 hours (B). The RAR-α/PML-RAR-α protein was detected by anti–RAR-α antibody with β-actin as the loading control. The number on the bottom indicates signal intensity of RAR-α or PML-RAR-α protein against β-actin.
